The global demand for Budesonide Market is presumed to reach the valuation of nearly USD XXX MN by 2026 from USD XXX MN in 2019 with a CAGR of X.XX% under the study period of 2020 - 2026.
Budesonide is an anti-inflammatory drug or medicine prescribed to prevent difficulty breathing, chest tightness, wheezing, and coughing caused by asthma. It works by preventing inflammation in the lungs. The dosage is available in suspension and powder form. The medicine is available only with a doctor's prescription. Budesonide is also used to treat certain bowel conditions; it effectively decreases symptoms such as pain and diarrhea. It is sold under the brand name: Pulmicort, Useris, and Pulmicort Flexhaler.
The key factor driving the growth of budesonide is the rising burden of asthma worldwide. Asthma is one of the common chronic diseases globally. As per WHO estimates, there were 417,918 deaths due to asthma, and more than 339 million people survive with asthma. Over 80% of asthma-associated deaths occur in low-and lower-middle-income countries. Growing FDA approval for Budesonide for other treatments such as Ulcerative Colitis and inhalation suspension further amplifies the demand. However, expiring patents and the availability of other similarly acting drugs restrains the growth of the market.
The report covers Porter’s Five Forces Model, Market Attractiveness Analysis and Value Chain analysis. These tools help to get a clear picture of the industry’s structure and evaluate the competition attractiveness at a global level.
Additionally, these tools also give inclusive assessment of each application/product segment in the global market of budesonide.
The entire budesonide market has been sub-categorized into type and applications. The report provides an analysis of these subsets with respect to the geographical segmentation. This research study will keep marketer informed and helps to identify the target demographics for a product or service.
- Nasal Spray
- Pill & Rectal Forms
- Respiratory Disease Treatment
- Nose Disease Treatment
- Inflammatory Bowel Disease Treatment
This section covers regional segmentation which accentuates on current and future demand for budesonide market across North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. Further, the report focuses on demand for individual application segment across all the prominent regions.
Europe Budesonide Market By Revenue (USD MN)
The research report also covers the comprehensive profiles of the key players in the market and an in-depth view of the competitive landscape worldwide. The major players in the budesonide market include AstraZeneca, Cosmo Pharmaceuticals, Teva, Mylan, Sandoz, Dr. Falk Pharma, Chiesi Farmaceutici S.p.A., Orion Corporation, Cipla, Synmosa Biopharma Corporation, Lunan Better Pharmaceutical, Shanghai Sine Promod Pharmaceutical. This section includes a holistic view of the competitive landscape that includes various strategic developments such as key mergers & acquisitions, future capacities, partnerships, financial overviews, collaborations, new product developments, new product launches, and other developments.
This market research report has been produced by gathering information on the basis of primary and secondary research. Secondary research has been done by using various sources which include (but not limited to) Company Websites, Paid Data Sources, Technical Journals, Financial Reports, SEC Filings, and other different industry publications.
If specific information is required which is not currently within the scope of the report, it can be provided as a part of customization.